Pancreatic Cancer Research

ResearcherHimeji Red Cross HospitalNo recent work listed

Toshihiko Matsumoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7397-1006; OpenAlex author ID A5039675116. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
13
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper

Papers 3

  1. A Retrospective Study Investigating the Safety and Efficacy of Nanoliposomal Irinotecan in Elderly Patients with Unresectable Pancreatic Cancer. First author DOI 10.3390/jcm12103477↗
  2. FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure. Co-author DOI 10.1097/mpa.0000000000001534↗
  3. [Gemcitabine plus S-1 combination therapy (GS therapy) for pancreatic cancer patients with high-grade hepatic metastasis]. Co-author PMID 22139487↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. So Yamaki · 1 shared paper, 2023 · strength 0.15
  2. Sohei Satoi · 1 shared paper, 2023 · strength 0.15
  3. Tsukasa Ikeura · 1 shared paper, 2023 · strength 0.15
  4. Takashi Ito · 1 shared paper, 2023 · strength 0.15
  5. Makoto Naganuma · 1 shared paper, 2023 · strength 0.15
  6. Koh Nakamaru · 1 shared paper, 2023 · strength 0.15
  7. Daisuke Hashimoto · 1 shared paper, 2023 · strength 0.15
  8. Tomohisa Yamamoto · 1 shared paper, 2023 · strength 0.15
  9. Tatsuki Ikoma · 1 shared paper, 2023 · strength 0.15
  10. Takayasu Kurata · 1 shared paper, 2023 · strength 0.15
  11. Hirofumi Morishita · 1 shared paper, 2020 · strength 0.11
  12. Akinori Asagi · 1 shared paper, 2011 · strength 0.03
  13. Haruo Iguchi · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.